Seattle Genetics Inc (SGEN)
ELDER RAY INDEX
Trading: SELL @ $56
Signal Strength: MEDIUM
Volatility indicators highlight potential moves of a stock which can either move sharply in the updwards or downwards direction. This indicator allows stocks to be compared on a level playing field to highlight high and low volatility. Normally, falling markets are more likely to be volatile than a rising markets due to the emotion that gets tied to trading. Use volatility indicators in conjunction with other indicators to reduce exposure to false moves.
Seattle Genetics Inc (NASDAQ:SGEN) Elder Ray Index is signalling a Bearish movement
A technical indicator developed by Alexander Elder that measures the amount of buying and selling pressure in the market. This indicator consists of two separate indicators known as bull power and bear power. These figures allow a trader to determine the position of the price relative to a certain exponential moving average (EMA).
Calculation: Elder Ray Index (ERI):
1) Bull Power = Daily High - n-period EMA;
2) Bear Power = Daily Low - n-period EMA;
PROFILE: Seattle Genetics Inc (SGEN)
Stock Exchange: NASDAQ
Company: Seattle Genetics Inc
Ticker Codes: | SGEN | NASDAQ:SGEN |
Seattle Genetics, Inc., a biotechnology company, focuses on the development and commercialization of targeted therapies for the treatment of cancer worldwide. It markets ADCETRIS, an antibody-drug conjugate for the treatment of relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma. The company also develops enfortumab vedotin, which is in Phase 1 clinical trial for Nectin-4-positive solid tumors, including bladder cancer; and tisotumab vedotin that is in Phase II clinical trial for patients with cervical cancer and solid tumors. In addition, it conducts phase 3 clinical trials of ADCETRIS which includes ECHELON-1 for patients with newly diagnosed advanced stage classical Hodgkin lymphoma; ECHELON-2 for patients with newly diagnosed CD30-expressing MTCL; and the CHECKMATE 812 for patients with relapsed or refractory or transplant-ineligible, and advanced classical Hodgkin lymphoma. Further, the company's earlier stage clinical pipeline includes six other ADC programs consisting of ladiratuzumab vedotin, denintuzumab mafodotin, SGN-CD19B, SGN-CD123A, SGN-CD33A, and SGN-CD352A, as well as two immuno-oncology agents, including SEA-CD40 and SGN-2FF. It has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline LLC; Pfizer, Inc., PSMA Development Company LLC; Takeda Pharmaceutical Company Limited, Unum Therapeutics, Inc., and Genmab A/S, as well as has co-development agreement with Agensys, Inc. Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.
Elder Ray IndexDownload
|ASNA Ascena Retail||2.73||8.8||3,524,561||-0.04||BEARISH|
|ASPS Altisource Portfolio||21.12||7.5||195,465||-1.11||BEARISH|
|CVTI Covenant Transportation Group||19.65||5.1||277,913||-0.46||BEARISH|
|SCVL Shoe Carnival Inc||32.79||4.9||417,377||-0.9||BEARISH|
|POWL Powell Inds Inc||25.57||4.8||35,700||-0.31||BEARISH|
|FOSL Fossil Group||16.57||4.7||1,175,192||-0.53||BEARISH|
|SPSC Sps Commerce||83.27||4.6||166,321||-0.35||BEARISH|